You are here

  • Home
  • Archive
  • Volume 10, Issue 8
  • Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments

Authors

  • Sylvain Nguyen Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Mathieu F Chevalier Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, SwitzerlandINSERM U976, HIPI Unit (Human Immunology, Pathophysiology and Immunotherapy), Hôpital Saint-Louis, Paris, France PubMed articlesGoogle scholar articles
  • Sulayman Benmerzoug Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Valérie Cesson Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Anna K Schneider Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Sonia-Cristina Rodrigues-Dias Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Florence Dartiguenave Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Ilaria Lucca Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Patrice Jichlinski Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Beat Roth Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Denise Nardelli-Haefliger Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Laurent Derré Urology Research Unit and Urology Biobank, Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articlesGoogle scholar articles

Citation

Nguyen S, Chevalier MF, Benmerzoug S, et al
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments
Journal for ImmunoTherapy of Cancer 2022;10:e004880. doi: 10.1136/jitc-2022-004880
Online issue publication 
November 15, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.